[TUT-7 early phase II clinical study for various solid tumors and hematologic malignancies]

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• TUT-7 (menogaril) is a novel anthracycline antitumor antibiotic.
• Early Phase II clinical trials are crucial for evaluating new cancer therapeutics.

Purpose of the Study:

• To assess the antitumor efficacy and safety of TUT-7 (menogaril) in patients with various malignant tumors.
• To determine response rates in specific cancer types including malignant lymphoma, prostate cancer, and uterine cervical cancer.

Main Methods:

• A nationwide early Phase II study involving 165 patients across 65 institutions.
• Patients received TUT-7 (menogaril) for 7 or 14 consecutive days at 75 or 100 mg/body/day, with at least two treatment courses.
• Antitumor efficacy was evaluated in 128 patients; adverse drug reactions and laboratory abnormalities were monitored.

Main Results:

• Malignant lymphoma: 1 complete response (CR) and 5 partial responses (PR) in 11 patients (54.5% response rate).
• Prostate cancer: 1 PR in 3 patients (33.3% response rate).
• Uterine cervical cancer: 2 PR in 12 patients (16.7% response rate).
• Frequent adverse events included digestive disorders (anorexia, nausea/vomiting) and malaise.
• Common laboratory abnormalities were myelosuppression (leukopenia, neutropenia).

Conclusions:

• TUT-7 (menogaril) demonstrated preliminary antitumor activity in malignant lymphoma, prostate, and uterine cervical cancers.
• The observed adverse drug reactions and laboratory abnormalities warrant careful monitoring during treatment.
• Further investigation is needed to establish the therapeutic role of TUT-7 (menogaril).